Physician profile
Mini Mathew
NPI 1154777001
$2,236.90
in general payments reported to CMS, 2019-2025
19 companies · $597 in 2025
The $597 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $122 · 2023: $406 · 2024: $894 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $299.19 | 2021-2025 | |
| Merz North America, INC. | $237.90 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $216.25 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $202.81 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $141.76 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $98.56 | 2021-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $93.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $85.72 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $50.38 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $44.83 | 2024-2025 | Voquezna |
| Amgen INC. | $41.84 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.47 | 2024 | Jardiance |
| Dexcom, INC. | $24.19 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $20.74 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $17.80 | 2021 | |
| Eisai INC. | $14.66 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.99 | 2023 | Quviviq |
| Genentech USA, INC. | $9.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.